GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Roy Herbst named director at Dartmouth Cancer Center
- In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt - FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
